LiquidCell Dx began building an evidence base for LiquidTME, a cell-free DNA methylation profiling assay designed to predict response to immune checkpoint inhibitors by characterizing tumor microenvironment “spatial ecotypes.” The startup says the approach was published in Nature by cofounders Aadel Chaudhuri (Mayo Clinic) and Aaron Newman (Stanford), using bulk and single-cell spatial transcriptomics across multiple tumor types.